View Older Stories View More Recent Stories
-
WGS: GeneDX Investors Should Contact Block & Leviton to Possibly Recover Losses
-
GeneDX Holdings Investigated for Possible Securities Fraud; Investors Should Contact Block & Leviton to Recover Losses
-
GeneDx (WGS) PT Lowered to $75 at Canaccord
-
GeneDx (WGS) PT Lowered to $90 at BTIG, Removed from Top Pick List
-
GeneDx Holdings (WGS) Misses Q1 EPS by 27c ; Offers Guidance
-
Piper Sandler on GeneDx (WGS): 'Aggressively buy on any reset sell-off'
-
Jefferies reiterates Buy on GeneDx (WGS) as analyst dismisses TAM saturation fears
-
Piper Sandler Reiterates Overweight Rating on GeneDx (WGS)
-
Jefferies Reiterates Buy Rating on GeneDx (WGS) on data moat, AI effeciency
-
GeneDx (WGS) PT Lowered to $170 at BTIG
-
Canaccord Genuity Reiterates Buy Rating on GeneDx (WGS)
-
TD Cowen on GeneDx (WGS): '4Q First Look: 4Q & '26 Guide Match Preannouncement'
-
GeneDx Holdings (WGS) Misses Q4 EPS by 70c ; Offers Guidance
-
Wells Fargo Upgrades GeneDx (WGS) to Overweight
-
GeneDx posts 41% revenue growth, issues 2026 guidance
-
GeneDx partners with Komodo Health to create rare disease dataset
-
GeneDx launches prenatal whole genome sequencing test
-
BTIG: 'we name GH and WGS as 2026 Top Picks'
-
GeneDx Holdings (WGS) Tops Q3 EPS by 8c; Offers Guidance
-
GeneDx (WGS) PT Raised to $170 at Guggenheim
-
GeneDx (WGS) PT Raised to $165 at BTIG
-
GeneDx Holdings (WGS) files mixed shelf
-
GeneDx receives FDA breakthrough device designation for genome tests
-
Canaccord Genuity Starts GeneDx (WGS) at Buy
-
Illumina constellation technology identifies hard-to-detect genetic variants
-
GeneDx names Dr. Mimi Lee as chief precision medicine officer
-
GeneDx joins $14.4 million NIH-funded genomic newborn screening study
-
GeneDx names Lisa Gurry as chief business officer
-
GeneDx (WGS) PT Raised at Piper Sandler; 'We Recommend Buying More on a Pullback'
-
Piper Sandler on GeneDx (WGS): 'Visibility to a Multiyear Growth Cycle'
-
GeneDx (WGS) PT Raised to $125 at BTIG
-
GeneDx Holdings (WGS) Tops Q2 EPS by 38c ; Offers Guidance
-
ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
Piper Sandler Starts GeneDx (WGS) at Overweight
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
GeneDx (WGS) PT Raised to $105 at Jefferies
-
GeneDx (WGS) announces AAP now recommends exome and genome sequencing
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
ROSEN, A LEADING NATIONAL FIRM, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
-
GeneDx Holdings (WGS) spreader July 70 and 80 calls as share price down 5.7%
-
Jefferies Upgrades GeneDx (WGS) to Buy
-
GeneDx Holdings (WGS) call put ratio 1 call to 1.3 puts as share price down
-
GeneDx (WGS) PT Lowered to $100 at BTIG
-
Increasing unusual put option volume: WGS WEN SCCO VNQ IP BBIO URNM BXP TTE SNAP FSLR NE
-
GeneDx Holdings (WGS) Misses Q1 EPS by 29c ; Offers Guidance
-
GeneDx to Acquire Fabric Genomics
